im with you resourced on thisthe management spin is incredible. it sounds like the classification under rule 13 was all gain with little painso why not rule 13 straight away?they cant have it both ways
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%